![]() The HOPE-2 trial gave repeated intravenous doses of cardiosphere-derived cells to patients with advanced Duchenne disease, most of whom could not walk. One of the interesting clinical trials reviewed involved giving cardiosphere-derived cells to patients with Duchenne muscular dystrophy, a disease that affects both heart and skeletal muscles.Ĭardiosphere-derived cells are a type of heart stromal/progenitor cells that have potent immunomodulatory, antifibrotic and regenerative activity in both diseased hearts and skeletal muscle. Such efforts are an attempt to reverse the inability of mature mammalian heart muscle cells to proliferate. ![]() For the third topic, authors discuss likely future experiments to replace a myocardial scar with heart muscle cells by "turning back the clock" of the existing cardiomyocytes, rather than trying to inject exogenous cells. Second is the current trend of using cell-derived products like exosomes rather than muscle cells to treat the injured heart. First are several recent clinical trials with intriguing results. In the review, the experts-coordinated by Jianyi "Jay" Zhang, M.D., Ph.D., chair of the University of Alabama at Birmingham Department of Biomedical Engineering-focus on three topics. The lack of muscle repair is due to the very limited ability of mammalian heart muscle cells to proliferate, except during a brief period around birth. The challenge is this: A heart attack kills heart muscle cells, leading to a scar that weakens the heart, often causing eventual heart failure. Yet hope remains that current and future strategies will yield clinical regenerative heart therapies, nine experts explain in a Journal of the American College of Cardiology state-of-the-art review, "Basic and translational research in cardiac repair and regeneration."
0 Comments
Leave a Reply. |